blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3164114

EP3164114 - PURIFIED THERAPEUTIC NANOPARTICLES AND PREPARATION METHODS THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.07.2021
Database last updated on 22.08.2024
FormerThe patent has been granted
Status updated on  07.08.2020
FormerGrant of patent is intended
Status updated on  11.05.2020
FormerExamination is in progress
Status updated on  10.12.2019
FormerRequest for examination was made
Status updated on  07.04.2017
FormerThe international publication has been made
Status updated on  28.12.2016
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024  [2024/29]
Applicant(s)For all designated states
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
No. 226, Huanghe Street
Shijiazhuang
Hebei 050035 / CN
[2017/19]
Inventor(s)01 / LI, Chunlei
No.226 Huanghe Street
Shijiazhuang Hebei 050035 / CN
02 / LI, Yanhui
No.226 Huanghe Street
Shijiazhuang Hebei 050035 / CN
03 / LIANG, Min
No.226 Huanghe Street
Shijiazhuang Hebei 050035 / CN
04 / WANG, Caixia
No.226 Huanghe Street
Shijiazhuang Hebei 050035 / CN
05 / WANG, Yajuan
No.226 Huanghe Street
Shijiazhuang Hebei 050035 / CN
06 / WANG, Shixia
No.226 Huanghe Street
Shijiazhuang Hebei 050035 / CN
07 / CHEN, Dongjian
No.226 Huanghe Street
Shijiazhuang Hebei 050035 / CN
08 / LI, Yongfeng
No.226 Huanghe Street
Shijiazhuang Hebei 050035 / CN
 [2017/19]
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[N/P]
Former [2020/37]HGF
1 City Walk
Leeds LS11 9DX / GB
Former [2017/19]HGF Limited
Delta House
50 West Nile Street
Glasgow G1 2NP / GB
Application number, filing date15815596.003.07.2015
[2017/19]
WO2015CN83255
Priority number, dateCN20141031404203.07.2014         Original published format: CN201410314042
WO2014CN9127717.11.2014         Original published format: PCT/CN2014/091277
US20151479064602.07.2015         Original published format: US201514790646
[2017/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016000653
Date:07.01.2016
Language:EN
[2016/01]
Type: A1 Application with search report 
No.:EP3164114
Date:10.05.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 07.01.2016 takes the place of the publication of the European patent application.
[2017/19]
Type: B1 Patent specification 
No.:EP3164114
Date:09.09.2020
Language:EN
[2020/37]
Search report(s)International search report - published on:CN07.01.2016
(Supplementary) European search report - dispatched on:EP14.06.2017
ClassificationIPC:A61K9/51, A61K31/337, A61K9/14, A61K9/19, A61K45/00, A61K47/42, A61P35/00
[2017/28]
CPC:
A61K9/5169 (EP,KR,US); A61K31/337 (EP,KR,US); A61K45/00 (RU);
A61K47/42 (RU); A61K9/08 (KR); A61K9/14 (RU);
A61K9/19 (KR,RU); A61P35/00 (EP,RU); B82Y5/00 (EP,US) (-)
Former IPC [2017/19]A61K9/14, A61K9/19, A61K45/00, A61K47/42, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/19]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:GEREINIGTE THERAPEUTISCHE NANOPARTIKEL UND HERSTELLUNGSVERFAHREN DAFÜR[2017/19]
English:PURIFIED THERAPEUTIC NANOPARTICLES AND PREPARATION METHODS THEREOF[2017/19]
French:NANOPARTICULES THÉRAPEUTIQUES PURIFIÉES ET LEURS PROCÉDÉS DE PRÉPARATION[2017/19]
Entry into regional phase28.12.2016National basic fee paid 
28.12.2016Search fee paid 
28.12.2016Designation fee(s) paid 
28.12.2016Examination fee paid 
Examination procedure15.01.2016Request for preliminary examination filed
International Preliminary Examining Authority: CN
28.12.2016Examination requested  [2017/19]
28.12.2016Date on which the examining division has become responsible
05.01.2018Amendment by applicant (claims and/or description)
13.12.2019Despatch of a communication from the examining division (Time limit: M03)
18.02.2020Reply to a communication from the examining division
12.05.2020Communication of intention to grant the patent
28.07.2020Fee for grant paid
28.07.2020Fee for publishing/printing paid
28.07.2020Receipt of the translation of the claim(s)
Opposition(s)10.06.2021No opposition filed within time limit [2021/33]
Fees paidRenewal fee
29.07.2017Renewal fee patent year 03
30.07.2018Renewal fee patent year 04
26.07.2019Renewal fee patent year 05
23.07.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.07.2015
AL09.09.2020
AT09.09.2020
CY09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
MK09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
TR09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
[2024/29]
Former [2024/22]HU03.07.2015
AL09.09.2020
AT09.09.2020
CY09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
MK09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2023/30]HU03.07.2015
AL09.09.2020
AT09.09.2020
CY09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2023/29]HU03.07.2015
AL09.09.2020
AT09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2022/18]AL09.09.2020
AT09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/37]AL09.09.2020
AT09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/36]AL09.09.2020
AT09.09.2020
CZ09.09.2020
EE09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SI09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/28]AL09.09.2020
AT09.09.2020
CZ09.09.2020
EE09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/25]AL09.09.2020
AT09.09.2020
CZ09.09.2020
EE09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/24]AT09.09.2020
CZ09.09.2020
EE09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
PT11.01.2021
Former [2021/23]CZ09.09.2020
EE09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
PT11.01.2021
Former [2021/22]CZ09.09.2020
EE09.09.2020
HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RO09.09.2020
RS09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
PT11.01.2021
Former [2021/21]HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RS09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
PT11.01.2021
Former [2021/18]HR09.09.2020
LT09.09.2020
LV09.09.2020
NL09.09.2020
PL09.09.2020
RS09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
Former [2021/10]HR09.09.2020
LT09.09.2020
LV09.09.2020
PL09.09.2020
RS09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
Former [2021/09]LT09.09.2020
SE09.09.2020
BG09.12.2020
NO09.12.2020
GR10.12.2020
Former [2021/07]LT09.09.2020
NO09.12.2020
Documents cited:Search[A]WO2011057709  (MERCK PATENT GMBH [DE], et al) [A] 1-32 * page 22, lines 12-25 *;
 [I]WO2011153010  (ABRAXIS BIOSCIENCES LLC [US], et al) [I] 1-32 * paragraphs [0277] , [0291] * * claims 1,21-23 *;
 [I]  - LI CHUNLEI ET AL, "Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: Is the crosslinked version more advantageous?", INTERNATIONAL JOURNAL OF PHARMACEUTICS, (201404), vol. 468, no. 1, doi:10.1016/J.IJPHARM.2014.04.010, ISSN 0378-5173, pages 15 - 25, XP029029801 [I] 1-32 * page 16, column 1, paragraph 6 - column 2, paragraph 2 * * page 18, column 2, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/j.ijpharm.2014.04.010
 [XA]  - STOLLENWERK M M ET AL, "Albumin-based nanoparticles as magnetic resonance contrast agents: I. Concept, first syntheses and characterisation", HISTOCHEMISTRY AND CELL BIOLOGY, SPRINGER, BERLIN, DE, (20100220), vol. 133, no. 4, ISSN 1432-119X, pages 375 - 404, XP019802809 [X] 1-3,12,14,17 * page 375, column 1, paragraph 1 * * page 380, column 1, paragraph 2 * * page 385 * [A] 4-11,13,15,16,18-32
 [A]  - AHMED O ELZOGHBY ET AL, "Albumin-based nanoparticles as potential controlled release drug delivery systems", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 157, no. 2, doi:10.1016/J.JCONREL.2011.07.031, ISSN 0168-3659, (20110720), pages 168 - 182, (20110801), XP028442118 [A] 1-32 * page 170, column 1, paragraph 3 *

DOI:   http://dx.doi.org/10.1016/j.jconrel.2011.07.031
 [A]  - NEHAL IBRAHIM ET AL, "Albumin-bound nanoparticles of practically water-insoluble antimalarial lead greatly enhance its efficacy", INTERNATIONAL JOURNAL OF PHARMACEUTICS, (20140108), vol. 464, no. 1-2, doi:10.1016/j.ijpharm.2014.01.001, ISSN 0378-5173, pages 214 - 224, XP055108520 [A] 1-32 * page 215, column 2, paragraph 2 - page 216, column 1, paragraph 1 * * page 217, column 2, paragraph 2 - page 218, column 1, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/j.ijpharm.2014.01.001
International search[Y]CN1736489  (ZHANG YANGDE [CN]) [Y] 19-29* Claim 1 *;
 [Y]CN102988996  (UNIV TSINGHUA) [Y] 21-23, 25-29 * Claim 4 *;
 [XY]CN103221042  (ABRAXIS BIOSCIENCE LLC) [X] 1-18, 32 * paragraphs [134], [138], [140] and [152]paragraphs [134], [138], [140] and [152] * [Y] 19-29
by applicantWO2011153010
    - LI CHUNLEI et al., "Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: Is the crosslinked version more advantageous?", International Journal of Pharmaceutics, (20140400), vol. 468, no. l, doi:10.1016/j.ijpharm.2014.04.010, pages 15 - 25, XP029029801

DOI:   http://dx.doi.org/10.1016/j.ijpharm.2014.04.010
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.